Results 51 to 60 of about 5,500,616 (251)

Engineering Microbial Particles for Next‐Generation Biomedical Platforms

Advanced Science, EarlyView.
Microbe‐derived particles (MDPs), which include extracellular vesicles, outer membrane vesicles, inclusion bodies, polysaccharide particles, and virus‐like particles, represent a rapidly expanding category of bioinspired nanomaterials. With their natural origin, intrinsic biocompatibility, and highly programmable functionality, MDPs serve as a ...
Yuting Li, Yunjie Lu, Ziyan Huang, Jianjiang Chen, Yanbin Liu, Lei Qin, Chao Wang, Yumin Wu   +7 more
wiley   +1 more source

The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study

The Korean Journal of Gastroenterology, 2018
Background /Aims: Direct-acting antiviral (DAA) therapy has been shown to achieve a high rate of sustained virologic response (SVR) and favorable outcomes in chronic hepatitis C (CHC) patients.
Seong Jun Park, Ah Ran Kim, Won Hyeok Choe, Jeong Han Kim, Byung Chul Yoo, So Young Kwon   +5 more
doaj   +1 more source

Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis

Viruses, 2023
A fixed-dose combination of sofosbuvir/velpatasvir (SOF/VEL) plus weight-based ribavirin (RBV) for 12 weeks is recommended for the treatment of patients with hepatitis C virus (HCV)-associated decompensated cirrhosis. However, large global studies, while
Steven Flamm, Eric Lawitz, Brian Borg, Michael Charlton, Charles Landis, K. Rajender Reddy, Mitchell Shiffman, Angel Alsina, Charissa Chang, Natarajan Ravendhran, Candido Hernandez, Christophe Hézode, Stacey Scherbakovsky, Renee-Claude Mercier, Didier Samuel   +14 more
doaj   +1 more source

Serum alpha-fetoprotein predicts virologic response to Hepatitis C treatment in HIV coinfected patients: [PDF]

, 2008
We explored the link between serum alpha-fetoprotein levels and virologic response in 383 HIV-hepatitis C virus coinfected patients. A low alpha-fetoprotein level (<5.0 ng/ml) was an independent predictor of sustained virologic response (odds ratio ...
Françoise Lunel-Fabiani, P. Cacoub, Lunel-Fabiani, Françoise, L. Piroth, Firouzé Bani-Sadr, G. Pialoux, Perronne, Christian, Pierre Bedossa, Dominique Salmon-Céron, Cacoub, Patrice, D. Salmon-Céron, Salmon-Céron, Dominique, Bani-Sadr, Firouzé, F. Bani-Sadr, Patrice Morand, P. Bedossa, Morand, Patrice, Patrice Cacoub, F. Lunel-Fabiani, Bedossa, Pierre, Lionel Piroth, Stanislas Pol, Fabrice Carrat, Christian Perronne, Carrat, Fabrice, Piroth, Lionel, Gilles Pialoux, C. Perronne, Pol, Stanislas, S. Pol, Pialoux, Gilles, F. Carrat, P. Morand   +32 more
core   +1 more source

Optimized Lipid Nanoparticles with Tail‐Modified Ionizable Lipids for Safer mRNA Delivery

Advanced Science, EarlyView.
Systematic engineering of hydrophobic tail architecture in vitamin B5‐derived ionizable lipids establishes a comprehensive structure–activity relationship framework for mRNA delivery. Combined lipidtail and formulation optimization identifies TM1‐OPT3‐C, a lipid nanoparticle platform that improves efficacy–safety balance through efficient mRNA delivery,
Seo‐Hyeon Bae, Jisun Lee, Jae‐Hun Ahn, Hosam Choi, Huijeong Choi, Jungmin Kim, Minho Kang, Ho Rim Oh, So Hyun Park, Eun Young Oh, Sanghyuk Jeon, Yeeun Lee, Yu‐Sun Lee, Na‐Young Lee, Hee‐Jin Bae, Jina Kwak, Jooil Kim, Nakyung Lee, Beomsun Kang, Ji‐Hye Kim, Eunsaem Song, Daesub Song, Hyunho Yoon, Sang‐Myeong Lee, Hyewon Youn, Kiyoun Lee, Byeong‐Cheol Kang, Jae‐Hwan Nam   +27 more
wiley   +1 more source

Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era

Gut and Liver, 2017
Background/AimsTo evaluate the era of direct acting antivirals (DAAs), we must understand the treatment patterns and outcomes of interferon-based therapy for hepatitis C virus (HCV) infection.
Eun Sun Jang, Young Seok Kim, Kyung-Ah Kim, Youn Jae Lee, Woo Jin Chung, In Hee Kim, Byung Seok Lee, Sook-Hyang Jeong   +7 more
doaj   +1 more source

Sustained virologic response for all-oral direct acting antiviral regimens.

, 2015
+Interferon ineligible/intolerant;*24 weeks of treatment; GT1 (a/b), genotype-1; GT2, genotype-2; GT3, genotype-3; N/A, not availableSustained virologic response for all-oral direct acting antiviral regimens.
Susanna Naggie (304827), Stacy M. Horner (178713)   +1 more
core   +1 more source

Dual Blockade of LILRB1 and LILRB2 Enhances Antiviral Immune Responses in SIV Infection

Advanced Science, EarlyView.
Dual LILRB1/B2 blockade with mac20G10 reshapes myeloid activation during acute SIV infection by targeting LILRB1 and LILRB2 on myeloid cells. This treatment enhances CD80 expression on selected myeloid subsets and increases plasma IFN‐λ, IL‐8, and IL‐1RA.
Florian Meurisse, Sixtine Coindre, Anne Wijkhuisen, Romain Marlin, Laure Fournier Le Ray, Juliette Pons, Melyssa Yaugel‐Novoa, Véronique Avettand‐Fenoel, Laurent Abi‐Rached, Anne‐Sophie Gallouet, Francis Relouzat, Mael Gourves, Asier Saez‐Cirion, Hisashi Arase, Gerard Zurawski, Sandra Zurawski, Nathalie Dereuddre‐Bosquet, Roger Le Grand, Stéphanie Simon, Olivier Lambotte, Benoit Favier   +20 more
wiley   +1 more source

Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy?

Diabetes, Metabolic Syndrome and Obesity, 2022
Rasha Youssef Hagag,1,* Ahmed Fawzy Selim,1,* Omneya Mohamed Darrag,1 Hassan Zied,2 Mohamed Sabry Aboelnasr1 1Department of internal medicine, Faculty of medicine, Tanta University, Tanta, Egypt; 2Kafr-Elsheikh Liver Institute, Kafr-Elsheikh, Egypt*These
Hagag RY, Selim AF, Darrag OM, Zied H, Aboelnasr MS   +4 more
doaj  

An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection [PDF]

Clinical and Molecular Hepatology, 2019
Background/Aims In the Republic of Korea, an estimated 231,000 individuals have chronic hepatitis C virus (HCV) infection. The aim of the present analysis was to evaluate the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) administered for 12 weeks
Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik, Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, Peggy Hwang   +11 more
doaj   +1 more source